lemma health

Upadacitinib, taken as a daily pill, significantly improved eczema symptoms compared to placebo. After 16 weeks, 60-70% of patients taking upadacitinib 15mg and 73-80% of patients taking 30mg had their eczema improve by at least 75%, compared to only 13-16% of patients taking placebo.

Upadacitinib (15mg or 30mg daily) showed rapid improvements in itch, pain, and other eczema symptoms within the first week of treatment. These improvements were maintained for 52 weeks, with patients also experiencing better sleep, quality of life, and mental health.

Upadacitinib was effective in treating moderate-to-severe eczema in adults, including patients who didn't respond well to other treatments like dupilumab or baricitinib. About 73% of patients achieved significant improvement in their eczema, and 69% experienced reduced itching after 16 weeks of treatment.

This study compared two medications for moderate-to-severe atopic dermatitis: oral upadacitinib and injectable dupilumab. Upadacitinib worked better and faster than dupilumab, with 72.4% of patients seeing major skin improvement after 16 weeks compared to 62.6% with dupilumab. However, upadacitinib had more side effects including acne and infections.

This study looked at the safety of upadacitinib across multiple conditions including atopic dermatitis by analyzing data from clinical trials. For atopic dermatitis patients, upadacitinib was generally well-tolerated, with acne being a notable side effect specific to AD patients.

Upadacitinib (15mg or 30mg daily) showed rapid improvements in itch, pain, and other eczema symptoms within the first week of treatment. These improvements were maintained for 52 weeks, with patients also experiencing better sleep, quality of life, and mental health.

Upadacitinib combined with topical steroids significantly improved itch, skin pain, sleep, and quality of life in patients with atopic dermatitis. The improvements were seen within 1-2 weeks and lasted for up to 52 weeks, with 62-84% of patients experiencing meaningful improvements depending on the dose.

Dupilumab significantly improved quality of life in adults with moderate-to-severe eczema. The improvements were meaningful in daily life, particularly reducing pain/discomfort, anxiety/depression, and helping with usual activities.

Dupilumab combined with topical steroids was significantly more effective than steroids alone in treating moderate-to-severe eczema. After 16 weeks, about 39% of patients on dupilumab had clear or almost clear skin compared to 12% on placebo, and these improvements lasted for the full year of treatment.

Dupilumab is an effective treatment for moderate-to-severe atopic dermatitis in adults and children as young as 6 months. Clinical trials show that 60-70% of patients achieve significant improvement in their eczema symptoms, including reduction in itch and skin clearance.

This study compared two medications for moderate-to-severe atopic dermatitis: oral upadacitinib and injectable dupilumab. Upadacitinib worked better and faster than dupilumab, with 72.4% of patients seeing major skin improvement after 16 weeks compared to 62.6% with dupilumab. However, upadacitinib had more side effects including acne and infections.

This real-world study compared the safety of dupilumab to conventional systemic treatments for atopic dermatitis over 5 years. Dupilumab showed fewer side effects related to circulatory, respiratory, and musculoskeletal systems, and infections compared to other treatments. However, it did have a higher risk of eye inflammation (conjunctivitis) compared to some other medications.

Dupilumab significantly improved eczema symptoms and skin healing over 16 weeks of treatment. The medication worked by reducing inflammation in the skin and helping restore normal skin barrier function.

Dupilumab is the first approved targeted biological therapy for atopic dermatitis in adults and children over 6 years with moderate-to-severe disease. It works by blocking specific inflammatory proteins (IL-4 and IL-13) and helps improve skin barrier function.

In children aged 6 months to 6 years with moderate-to-severe eczema, dupilumab with low-strength steroid cream worked significantly better than placebo. After 16 weeks, 28% of children on dupilumab had clear or almost clear skin compared to only 4% on placebo, and 53% had major improvement in their eczema compared to 11% on placebo.

This study showed that taking dupilumab every 2 weeks maintains improvements in eczema symptoms over 36 weeks. About 72% of patients maintained their improvement when taking dupilumab every 2 weeks, compared to only 30% of patients who stopped treatment. The study found that taking dupilumab less frequently (every 4 or 8 weeks) was not as effective as taking it every 2 weeks.

In children with eczema, both tacrolimus ointment and hydrocortisone cream improved quality of life. Tacrolimus was better at reducing certain inflammatory markers in the blood compared to hydrocortisone, though both treatments were effective.

Both tacrolimus and mild corticosteroids were safe and effective in treating young children with moderate-to-severe eczema. Children who showed early signs of allergies (sensitization) had better results with tacrolimus than with corticosteroids after 12 months of treatment.

Tacrolimus 0.03% ointment was more effective than Hydrocortisone 1% in treating children with atopic dermatitis. After 3 weeks of treatment, Tacrolimus reduced disease severity by 56% compared to 27% with Hydrocortisone.

This 10-year study found that children using tacrolimus cream (Protopic) for eczema did not have an increased risk of developing cancer compared to the general population. No cases of lymphoma were reported.

This study found that using topical calcineurin inhibitors (like Protopic) for treating atopic dermatitis does not increase the risk of skin cancer compared to using topical corticosteroids or using no treatment. This suggests that these medications are safe to use in terms of skin cancer risk in adults.

Both tacrolimus and mild corticosteroids were safe and effective in treating young children with moderate-to-severe eczema. Children who showed early signs of allergies (sensitization) had better results with tacrolimus than with corticosteroids after 12 months of treatment.

This study compared two eczema treatments (tacrolimus 0.03% and crisaborole) in children with mild to moderate eczema. While both medications improved eczema symptoms, tacrolimus showed better results in improving quality of life for both children and their caregivers.

This 5-year study compared pimecrolimus cream with regular steroid creams in young children with mild-to-moderate eczema. While both treatments were generally safe, steroid creams worked slightly better, and children using pimecrolimus had more skin infections and respiratory issues.

Pimecrolimus cream was as effective as topical steroids in treating mild-to-moderate eczema in infants over a 5-year period. Both treatments helped more than 85% of patients achieve clear or almost clear skin, but pimecrolimus required much fewer steroid days (7 vs 178), making it a safer long-term option.

This 5-year study compared pimecrolimus cream with regular steroid creams in young children with mild-to-moderate eczema. While both treatments were generally safe, steroid creams worked slightly better, and children using pimecrolimus had more skin infections and respiratory issues.

Pimecrolimus cream was as effective as topical steroids in treating mild-to-moderate eczema in infants over a 5-year period. Both treatments helped more than 85% of patients achieve clear or almost clear skin, but pimecrolimus required much fewer steroid days (7 vs 178), making it a safer long-term option.

Pimecrolimus cream was as effective as topical corticosteroids in treating atopic dermatitis in Chinese infants. After 26 weeks, about 83% of infants treated with Pimecrolimus showed improvement, which was similar to the 89% improvement seen with corticosteroids.

This is a commentary on a 5-year safety study of pimecrolimus in treating atopic dermatitis. The article discusses how despite pimecrolimus being available for over a decade, there's still uncertainty about when to use it versus topical steroids, particularly for sensitive areas like the face and eyelids.

This study found that using topical calcineurin inhibitors (like Protopic) for treating atopic dermatitis does not increase the risk of skin cancer compared to using topical corticosteroids or using no treatment. This suggests that these medications are safe to use in terms of skin cancer risk in adults.

Lebrikizumab was effective in treating moderate-to-severe eczema in two large clinical trials. After 16 weeks, about 33-43% of patients achieved clear or almost clear skin compared to 11-13% on placebo. The medication also helped reduce itch, and while it caused some eye inflammation (conjunctivitis), most side effects were mild.

Lebrikizumab was effective in treating moderate-to-severe eczema over 52 weeks. After initial treatment, patients maintained good results whether they received the drug every 2 weeks or every 4 weeks, with about 75-80% of patients maintaining clear or almost clear skin.

Lebrikizumab helped improve itching and sleep quality in patients with moderate-to-severe eczema. Patients who experienced less itching and better sleep also reported better quality of life after 16 weeks of treatment.

Lebrikizumab, a medication that targets IL-13, significantly improved moderate-to-severe atopic dermatitis symptoms in adults. After 16 weeks, about 60% of patients taking lebrikizumab had clear or almost clear skin compared to 16% taking placebo.

This analysis looked at the safety of lebrikizumab across eight clinical trials in patients with moderate-to-severe eczema. The medication was generally safe, with most side effects being mild or moderate. The most common side effect specific to lebrikizumab was conjunctivitis (eye inflammation), occurring in about 8.5% of patients.

Lebrikizumab was found to be generally safe for treating moderate-to-severe atopic dermatitis in adults and adolescents. The most common side effect was conjunctivitis (eye inflammation), occurring in 8.5% of treated patients compared to 2.5% in placebo. Most side effects were mild or moderate.

Lebrikizumab helped maintain clear or almost clear skin in patients with moderate-to-severe eczema for up to 2 years. About half of the patients achieved completely clear skin, and more than 55% reported having no or minimal itching after 2 years of treatment.

Lebrikizumab was effective in treating moderate-to-severe eczema over 52 weeks. After initial treatment, patients maintained good results whether they received the drug every 2 weeks or every 4 weeks, with about 75-80% of patients maintaining clear or almost clear skin.

Ruxolitinib cream showed significant improvement in eczema symptoms compared to vehicle (placebo cream). The highest dose (1.5% twice daily) reduced eczema severity by 71.6% after 4 weeks, and patients experienced itch relief within 36 hours of starting treatment.

Ruxolitinib cream, when applied to the skin of patients with atopic dermatitis, shows very low levels in the blood, suggesting it mainly works locally on the skin. This means it's less likely to cause the side effects typically seen with oral JAK inhibitor medications.

Ruxolitinib cream was effective in treating eczema in teenagers, with about 51% achieving clear or almost clear skin after 8 weeks compared to 14% using a placebo cream. The medication started working quickly, reducing itch from day 2, and continued to work well for up to 52 weeks with few side effects.

Ruxolitinib cream was tested in patients with moderate to severe eczema covering at least 25% of their body. After 56 days of treatment, about 95% of patients showed significant improvement in their eczema symptoms. The cream was generally safe to use, with only a few patients experiencing treatment-related side effects.

Ruxolitinib cream, when applied to the skin of patients with atopic dermatitis, shows very low levels in the blood, suggesting it mainly works locally on the skin. This means it's less likely to cause the side effects typically seen with oral JAK inhibitor medications.

Ruxolitinib cream was tested in patients with moderate to severe eczema covering at least 25% of their body. After 56 days of treatment, about 95% of patients showed significant improvement in their eczema symptoms. The cream was generally safe to use, with only a few patients experiencing treatment-related side effects.

Ruxolitinib cream improved itch and skin pain within 12 hours of application in people with mild-to-moderate eczema. The treatment also improved sleep and quality of life within 2 weeks, and these benefits lasted for up to 52 weeks.

Ruxolitinib cream, applied twice daily, quickly reduced itch in people with mild to moderate eczema. The cream started working within 12 hours and continued to improve itch symptoms over 8 weeks. The stronger version (1.5%) worked better than the weaker version (0.75%) and both worked better than the placebo cream.

Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.

Nemolizumab, when used with topical treatments, reduced itching by 43% compared to 21% with placebo after 16 weeks. The medication also improved eczema severity and sleep quality in Japanese patients with moderate-to-severe atopic dermatitis.

Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.

Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.

Nemolizumab, given as an injection every 4 weeks along with topical treatments, helped reduce itching by 66% and eczema severity by 78% over 68 weeks in patients with moderate-to-severe atopic dermatitis. The improvements lasted even after treatment ended, and the medication was generally safe to use.

Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.

Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.

Nemolizumab is a new drug that targets IL-31, which is involved in causing eczema symptoms. The drug shows good results in reducing itch quickly and improving skin condition, with mostly mild side effects.

Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.

Tralokinumab, a medication given every 2 weeks, helped improve severe eczema in adults who didn't respond well to topical treatments. After 16 weeks, about 25-33% of patients saw a significant improvement in their eczema symptoms compared to 11-13% who received placebo. Most patients who responded well at 16 weeks maintained their improvement through 52 weeks of treatment.

Tralokinumab effectively treated moderate-to-severe eczema in adults over 28 weeks, working well for both new patients and those who previously used dupilumab. About 76% of patients achieved clear or almost clear skin, though some patients (27.4%) had to stop treatment due to side effects or lack of effectiveness.

Tralokinumab was found to be safe for treating moderate-to-severe atopic dermatitis based on data from five clinical trials. The most common side effects were upper respiratory infections and eye inflammation (conjunctivitis), but serious side effects were rare and similar to placebo.

Tralokinumab effectively treated moderate-to-severe eczema in adults over 28 weeks, working well for both new patients and those who previously used dupilumab. About 76% of patients achieved clear or almost clear skin, though some patients (27.4%) had to stop treatment due to side effects or lack of effectiveness.

Tralokinumab with topical steroids showed continuous improvement in eczema symptoms over 32 weeks. By week 32, about 70% of patients saw a 75% improvement in their eczema, and about 50% saw a 90% improvement. The treatment helped reduce sleep problems and improved quality of life.

Tralokinumab effectively treated moderate-to-severe eczema in adults over 28 weeks, working well for both new patients and those who previously used dupilumab. About 76% of patients achieved clear or almost clear skin, though some patients (27.4%) had to stop treatment due to side effects or lack of effectiveness.

Tralokinumab with topical steroids showed continuous improvement in eczema symptoms over 32 weeks. By week 32, about 70% of patients saw a 75% improvement in their eczema, and about 50% saw a 90% improvement. The treatment helped reduce sleep problems and improved quality of life.

Tralokinumab, either alone or with topical steroids, showed rapid improvement in itch and sleep quality for patients with moderate-to-severe eczema. Patients started experiencing relief from itch as early as 1-2 weeks into treatment, and improvements in sleep were seen within 2 weeks.

Tapinarof cream 1% applied once daily was effective in treating moderate to severe eczema in both adults and children as young as 2 years old. After 8 weeks, about 46% of patients using tapinarof had clear or almost clear skin compared to only about 16% using placebo cream. The medication was generally safe with mostly mild side effects.

Tapinarof cream 1%, applied once daily, was effective in treating moderate to severe eczema in both adults and children as young as 2 years old. After 8 weeks, about 46% of patients using tapinarof had clear or almost clear skin, compared to only about 16% using the vehicle cream.

Tapinarof cream 1% applied once daily helped reduce itching and improve sleep in people with atopic dermatitis. About one-third of patients achieved minimal to no itching after 8 weeks of treatment, compared to only 14-17% of those using a placebo cream.

Tapinarof cream 1% applied once daily showed rapid improvement in itch symptoms in patients with atopic dermatitis, with effects seen as early as 24 hours after first use. The improvement in itch continued to increase through 8 weeks of treatment.

Tapinarof cream 1% applied once daily was effective in treating moderate to severe eczema in both adults and children as young as 2 years old. After 8 weeks, about 46% of patients using tapinarof had clear or almost clear skin compared to only about 16% using placebo cream. The medication was generally safe with mostly mild side effects.

Tapinarof cream 1% was tested for skin safety in healthy adults. The cream was found to be safe, causing only very mild skin irritation, and did not cause allergic reactions or increased sensitivity to sunlight.

Tapinarof cream 1% applied once daily was effective in treating atopic dermatitis across all skin colors and races in both adults and children as young as 2 years old. The medication worked significantly better than the vehicle (cream without active ingredient) in clearing or almost clearing eczema symptoms.

Tapinarof cream 1% applied once daily was effective in treating atopic dermatitis across all skin colors and races, including children as young as 2 years old. About 40-50% of patients achieved clear or almost clear skin after 8 weeks of treatment, which was significantly better than the placebo group.

Roflumilast cream (0.15% and 0.05%) was tested as a once-daily treatment for mild to moderate eczema. While the primary goal wasn't met, the cream showed promising improvements in eczema symptoms with very few side effects.

Roflumilast cream (0.15% and 0.05%) was tested as a once-daily treatment for mild to moderate eczema. While the primary goal wasn't met, the cream showed promising improvements in eczema symptoms with very few side effects.

Roflumilast cream (0.15% and 0.05%) was tested as a once-daily treatment for mild to moderate eczema. While the primary goal wasn't met, the cream showed promising improvements in eczema symptoms with very few side effects.

Crisaborole 2% ointment is effective for treating mild to moderate atopic dermatitis in patients aged 2 years and older. The medication works by reducing inflammation and itching, with about 30-50% of patients achieving clear or almost clear skin after 4 weeks of treatment.

Crisaborole ointment was more effective than placebo in treating mild to moderate eczema in patients aged 2 years and older. About 32% of patients using crisaborole achieved clear or almost clear skin compared to 18-25% using placebo, and the medication showed a good safety profile.

Crisaborole 2% ointment is effective for treating mild to moderate atopic dermatitis in patients aged 2 years and older. The medication works by reducing inflammation and itching, with about 30-50% of patients achieving clear or almost clear skin after 4 weeks of treatment.

Crisaborole ointment was tested in infants aged 3-24 months with mild-to-moderate eczema. The treatment was well-tolerated with mostly mild side effects, and about 30% of patients achieved clear or almost clear skin after 28 days of treatment.

Once-daily crisaborole ointment helped prevent eczema flares for longer compared to vehicle (placebo), with patients staying flare-free for about 111 days versus 30 days. Patients using crisaborole had fewer flares overall and more flare-free days during the year-long study.

Once-daily crisaborole ointment was tested as a long-term maintenance treatment for mild-to-moderate eczema. Patients using crisaborole stayed flare-free for longer (111 days vs 30 days) compared to those using a placebo ointment, and had fewer flares over the course of a year.

Crisaborole 2% ointment is effective for treating mild to moderate atopic dermatitis in patients aged 2 years and older. The medication works by reducing inflammation and itching, with about 30-50% of patients achieving clear or almost clear skin after 4 weeks of treatment.

Crisaborole ointment 2% was more effective than placebo in treating mild-to-moderate eczema in children and teenagers. Patients using crisaborole showed faster and greater improvements in both skin appearance and itch compared to those using vehicle (placebo), with benefits seen as early as 8 days after starting treatment.